MIRA Pharmaceuticals Inc./$MIRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Ticker
$MIRA
Sector
Primary listing
Employees
-
Headquarters
Website
MIRA Metrics
BasicAdvanced
$41m
-
-$1.04
-
-
Price and volume
Market cap
$41m
52-week high
$2.45
52-week low
$0.90
Average daily volume
123k
Financial strength
Current ratio
82.156
Quick ratio
81.966
Profitability
Management effectiveness
Return on assets (TTM)
-112.66%
Return on equity (TTM)
-184.32%
Valuation
Price to book
4.4
Price to tangible book (TTM)
4.4
Price to free cash flow (TTM)
-6.937
Free cash flow yield (TTM)
-14.42%
Free cash flow per share (TTM)
-0.141
Growth
Earnings per share change (TTM)
109.94%
3-year earnings per share growth (CAGR)
26.18%
MIRA News
AllArticlesVideos
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
Accesswire·1 day ago
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
Accesswire·2 weeks ago
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
Accesswire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs